Pharma Company Licenses UArizona Method for Treating Parkinson ' s Disease with Ketamine

Pharma Company Licenses UArizona Method for Treating Parkinson's Disease with Ketamine
Today
In pre-clinical studies,  researchers found that low-dose ketamine infusions can improve pain, depression and levodopa-induced dyskinesia in Parkinson ' s patients.201408834_Sherman-Scott-1140.jpg
Dr. Scott Sherman
College of Medicine - TucsonHealthScience and TechnologyCollege of Medicine - TucsonCommercializationTech Launch Arizona
Media contact(s)Paul Tumarkin
Tech Launch [e-mail]520-626-8770Researchers at the University of Arizona  College of Medicine – Tucson have developed a method of using ketamine in the treatment of Parkinson ' s disease. The university has entered into an exclusive licensing agreement with Pharmather Inc., a subsidiary of Newscope Capital Corporation, for the development and commercialization of the method.Ketamine is a Food and Drug Administration-approved drug, and prior clinical reports suggest that low-dose ketamine infusions are well-tolerated and can help treat pain and depression, which are common in Parkinson ' s disease patients.201402805_Falk-Torsten-18.jpg
Dr. Torsten Falk
College of Medicine - TucsonDr.Scott Sherman andTorsten Falk, both associate professors in the College of Medicine – Tucson, worked with the university ' s technology commercialization office,  Tech Launch Arizona, to file a patent application based on the results from preclinical data and five case studies in Parkinson ' s disease p...

Source: The University of Arizona: Health - November 2, 2020 Category: Universities & Medical Training Authors: tumarkin Source Type: research